We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pulmonary Biomarker Surfactant Protein-B Is Used for Diagnosis

By LabMedica International staff writers
Posted on 10 Dec 2008
Print article
Roche Diagnostics (Rotkreuz, Switzerland) and an Australian Biotech company, Southern Medical Diagnostics (SMD; Walkerville, Australia) signed licensing agreements on diagnostic applications of Surfactant Protein-B.

According to the agreements, Roche will have semi-exclusive worldwide rights for diagnostic applications of Surfactant Protein-B (SP-B) in lung disorders; SMD will have worldwide rights to key test-components developed by Roche, which SMD may exclusively use for SP-B applications.

A lung-specific protein and a key functional component of the alveolus, SP-B is present at very low concentrations in the serum of healthy people. It is released into the blood stream as a result of lung injury and is significantly increased in primary and secondary lung disorders affecting mainly the lung parenchyma. This includes the alveolocapillary system, such as chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and heart failure. Changes of lung disorders can be monitored by measuring levels of SP-B in the blood.

Together with B-type natriuretic peptide (BNP or NT-proBNP) tests, SP-B helps to discriminate between cardiac and non-cardiac causes of dyspnea.

"Roche Diagnostics believes that tests for Surfactant Protein-B will be very valuable in the diagnosis, differential diagnosis, and monitoring of patients with primary and secondary pulmonary disorders," said Dirk Ehlers, head of Roche Professional Diagnostics." He added, "The SP-B assay will allow earlier recognition of cardio-pulmonary conditions and thereby prepare the basis for improved treatment in the future."

Roche is one of the world's leading healthcare groups in the fields of diagnostics and pharmaceutics. The company is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology.

Southern Medical Diagnostics Pty Ltd. is a private Australian company specializing in the development and out-licensing of novel diagnostic technologies.

Related Links:
Roche Diagnostics
Southern Medical Diagnostics

Gold Member
Turnkey Packaging Solution
HLX
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Toxoplasma Gondii Test
Toxo IgG ELISA Kit
New
Centrifuge
Centrifuge 5430/ 5430 R

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.